Anixa: Theoretical Study Shows Effectiveness Of Its Compounds Against Delta Variant

(RTTNews) - Anixa Biosciences, Inc. (ANIX) said a genomic variant analysis indicates that the company's potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. The company's program in collaboration with MolGenie, focuses on identifying small molecule inhibitors of Mpro, the main protease of the virus.

Amit Kumar, CEO of Anixa Biosciences, said: "While this program is relatively early-stage in development, we have already received inbound calls from pharmaceutical companies and funding agencies interested in collaborating at the right time."

Shares of Anixa Biosciences were up 14% in pre-market trade on Wednesday.